Compare CHE & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHE | KRYS |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.3B |
| IPO Year | N/A | 2017 |
| Metric | CHE | KRYS |
|---|---|---|
| Price | $448.08 | $284.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $555.50 | $250.50 |
| AVG Volume (30 Days) | 129.6K | ★ 291.8K |
| Earning Date | 02-25-2026 | 02-18-2026 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | N/A | ★ 275.72 |
| EPS | ★ 18.95 | 6.66 |
| Revenue | ★ $2,530,634,000.00 | $373,164,000.00 |
| Revenue This Year | $5.91 | $36.14 |
| Revenue Next Year | $6.21 | $42.38 |
| P/E Ratio | ★ $23.47 | $43.40 |
| Revenue Growth | 6.45 | ★ 54.51 |
| 52 Week Low | $408.42 | $122.80 |
| 52 Week High | $623.61 | $295.98 |
| Indicator | CHE | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 65.40 |
| Support Level | $427.85 | $271.52 |
| Resistance Level | $454.61 | $295.98 |
| Average True Range (ATR) | 11.75 | 12.40 |
| MACD | 0.22 | 0.91 |
| Stochastic Oscillator | 66.61 | 79.43 |
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. Through its subsidiaries, the company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.